Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea

Lee Kyong Joo; Cho Jae Hee; Lee Sang Hyub; Song Si Young; Lee Kwang Hyuk; Jeong Seok; Ryu Ji Kon; Woo Sang Myung; Bang Seungmin; Lee Jong Kyun; Lee Tae Hoon; Paik Woo Hyun; Kim Yong Tae; Lee Woo Jin

首页> 外文期刊>Cancer chemotherapy and pharmacology. >Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea

【24h】

Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea

机译：高血管血症患者晚期，无血齿胰腺神经内分泌肿瘤患者的临床结果：韩国多中心研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Everolimus is a standard treatment option for advanced pancreatic neuroendocrine tumors (pNETs). This multicenter study evaluated the efficacy and safety of everolimus in low and intermediate grade advanced pNETs.

机译：埃弗洛米斯是晚期胰腺神经内分泌肿瘤（PNets）的标准治疗选择。该多中心的研究评估了血对血管司的疗效和安全性低，中间级先进的PNET。

著录项

来源
《Cancer chemotherapy and pharmacology.》 |2017年第4期|共7页
作者
Lee Kyong Joo; Cho Jae Hee; Lee Sang Hyub; Song Si Young; Lee Kwang Hyuk; Jeong Seok; Ryu Ji Kon; Woo Sang Myung; Bang Seungmin; Lee Jong Kyun; Lee Tae Hoon; Paik Woo Hyun; Kim Yong Tae; Lee Woo Jin;
展开▼
作者单位

Yonsei Univ Dept Internal Med Wonju Coll Med Wonju South Korea;

Gachon Univ Dept Internal Med Gil Med Ctr Incheon South Korea;

Seoul Natl Univ Dept Internal Med 101 Daehak Ro Seoul 03080 South Korea;

Yonsei Univ Dept Internal Med Coll Med Seoul South Korea;

Sungkyunkwan Univ Dept Internal Med Samsung Med Ctr Sch Med Seoul South Korea;

Inha Univ Dept Internal Med Coll Med Incheon South Korea;

Seoul Natl Univ Dept Internal Med 101 Daehak Ro Seoul 03080 South Korea;

Natl Canc Ctr Ctr Liver Canc 323 Ilsan Ro Goyang 10408 South Korea;

Yonsei Univ Dept Internal Med Coll Med Seoul South Korea;

Sungkyunkwan Univ Dept Internal Med Samsung Med Ctr Sch Med Seoul South Korea;

Soon Chun Hyang Univ Cheonan Hosp Dept Internal Med Coll Med Cheonan South Korea;

Seoul Natl Univ Dept Internal Med 101 Daehak Ro Seoul 03080 South Korea;

Seoul Natl Univ Dept Internal Med 101 Daehak Ro Seoul 03080 South Korea;

Natl Canc Ctr Ctr Liver Canc 323 Ilsan Ro Goyang 10408 South Korea;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
Everolimus; Pancreatic neuroendocrine tumor; World Health Organization classification; Tumor grade; Prognosis;

机译：血血管血清;胰腺神经内分泌肿瘤;世界卫生组织分类;肿瘤等级;预后;

相似文献

外文文献
中文文献
专利

1. Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea [J] . Lee Kyong Joo, Cho Jae Hee, Lee Sang Hyub, Cancer chemotherapy and pharmacology. . 2017,第4期

机译：高血管血症患者晚期，无血齿胰腺神经内分泌肿瘤患者的临床结果：韩国多中心研究
2. Everolimus (EVE) for Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) from a Randomized, Double-Blind, Placebo (PBO)-Controlled, Multicenter Phase 3 RADIANT-3 Study [J] . Yao J. C., Pavel M., Lombard-Bohas C., Neuroendocrinology: International Journal for Basic and Clinical Studies on Neuroendocrine Relationships . 2015,第1a2期

机译：依维莫司（EVE）用于晚期，进行性胰腺神经内分泌肿瘤（pNET）：一项随机，双盲，安慰剂（PBO）控制的多中心3期RADIANT-3研究的最终总生存期（OS）
3. Randomized Phase II Study of Everolimus (E) Versus Everolimus plus Bevacizumab (E plus B) in Patients (Pts) With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET), CALGB 80701 (Alliance) [J] . Kulke Matthew H., Niedzwiecki Donna, Foster Nathan R., Pancreas . 2016,第3期

机译：依维莫司（E）与依维莫司+贝伐珠单抗（E + B）在患有局部晚期或转移性胰腺神经内分泌肿瘤（pNET），CALGB 80701（联盟）的患者（Pts）中的随机II期研究
4. Percutaneous Coronary Interventionfor Acute Myocardial Infarctionin the Elderly:Comparison on Clinical Outcome betweenYounger Patients, Septuagenarians Patientsand Octogenarians Patients:Multicenter Registry in Japan [C] . S. Nakamura, M. Hirosc, E. Saito, International Congress on Coronary Artery Disease . 2003

机译：急性心肌梗死的经皮冠状动脉介入性老年人：患者患者患者临床结果的比较，Septuagenss患者和八分类患者：日本多中心登记处
5. ISL-1 Expression as a Potential Prognostic Factor in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors [D] . Assi, Hussein. 2020

机译：ISL-1表达作为具有良好分化的胰腺神经内分泌肿瘤患者的潜在预后因素
6. A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Trial (RADIANT-3) of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: Updated Safety and Overall Survival Results [O] . Jonathan R. Strosberg, James C. Yao 2012

机译：晚期胰腺神经内分泌肿瘤患者中依维莫司的一项随机双盲安慰剂对照多中心III期试验（RADIANT-3）：更新的安全性和总体生存结果
7. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas [O] . Do-Youn Oh, Tae-Won Kim, Young Suk Park, 2012

机译：阶段2血尿症神经内分泌肿瘤患者血尿症单药治疗/鸟粪瘤/巴拉邦族瘤

Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅